Adalimumab biosimilar in inflammatory bowel disease

Abstract

The use of biosimilars of monoclonal antibodies against TNFα is one of the key pillars in the treatment of inflammatory bowel disease (IBD), and, more generally, in all immune-mediated diseases. In relation to IBD, the Biosimilar Council estimated that the increasing availability of biosimilars has provided a potential saving between US$53 and $106 billion in western Europe and the USA between 2015 and 2020.1 The substantial cost reduction for treating IBD has increased access to biologics, leading to improvements in clinical outcomes for patients and greater health-care system efficiency.